Diabetes is often called the “silent killer” because people who have it are often unaware they are affected. According to the American Diabetes Association, diabetes affects 26 million people – including children – in the United States. Approximately o…
Author: OphthalmologyWeb
Topcon To Release EyeRoute Synergy At Vision Expo East, New York
Oakland, New Jersey – March 18, 2011 – In addition to sponsoring continuing educational events at the Vision Expo and Conference in New York (March 16-20), Topcon will be releasing EyeRoute Synergy, the company announced today. Due to take place at Jac…
Perimetric Glaucoma Best Detected With OCT Through Average Peripapillary RNFL Thickness
The average thickness of the peripapillary retinal nerve fiber layer is the best optical coherence tomography parameter for determining perimetric glaucoma, a study found.
Ellex To Deliver New Diagnostic Ultrasound Mode At ASCRS
Adelaide, Australia, 23 March 2011 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in ophthalmic laser and ultrasound technology, today announced that it will introduce a new diagnostic ultrasound mode for its leading Eye CubedT system at the…
Ellex To Deliver New Diagnostic Ultrasound Mode At ASCRS
Adelaide, Australia, 23 March 2011 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in ophthalmic laser and ultrasound technology, today announced that it will introduce a new diagnostic ultrasound mode for its leading Eye CubedT system at the…
Eyelid Surgery Boosts QOL In Facial Paralysis
For patients who couldn’t close their eyes because of facial paralysis, surgery produced a significant improvement quality of life as well as in dryness and irritation, results of a small clinical study showed.
Ellex To Deliver New Diagnostic Ultrasound Mode At ASCRS
Adelaide, Australia, 23 March 2011 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in ophthalmic laser and ultrasound technology, today announced that it will introduce a new diagnostic ultrasound mode for its leading Eye CubedT system at the…
Perimetric Glaucoma Best Detected With OCT Through Average Peripapillary RNFL Thickness
The average thickness of the peripapillary retinal nerve fiber layer is the best optical coherence tomography parameter for determining perimetric glaucoma, a study found.
Topcon To Release EyeRoute Synergy At Vision Expo East, New York
Oakland, New Jersey – March 18, 2011 – In addition to sponsoring continuing educational events at the Vision Expo and Conference in New York (March 16-20), Topcon will be releasing EyeRoute Synergy, the company announced today. Due to take place at Jac…
Silence Therapeutics’ Partner Quark Pharmaceuticals Announces Results From Phase 2 PF-04523655 Study In Diabetic Macular Edema
Silence Therapeutics plc (AIM: SLN) (“Silence” or the “Company”) a leading global RNA interference (RNAi) therapeutics company, announces today that its partner, Quark Pharmaceuticals, has received results from a prospective randomized Phase 2 trial, t…
Silence Therapeutics’ Partner Quark Pharmaceuticals Announces Results From Phase 2 PF-04523655 Study In Diabetic Macular Edema
Silence Therapeutics plc (AIM: SLN) (“Silence” or the “Company”) a leading global RNA interference (RNAi) therapeutics company, announces today that its partner, Quark Pharmaceuticals, has received results from a prospective randomized Phase 2 trial, t…
Heidelberg Engineering Announces Expansion To New US Corporate Headquarters
Vista, CA – Due to continuing, rapid growth, Heidelberg Engineeringannounced plans to move its corporate US headquarters to the Carlsbad Research Center in Carlsbad, California at the beginning of April. The company will also move its service center to…
Femtosecond-Guided LASIK Enhancement Has Minimal Trauma, Reduced Rate Of Epithelial Ingrowth
A new technique of LASIK enhancement using a femtosecond laser allows for easy flap re-lifting, minimal trauma and significantly reduced rate of epithelial ingrowth, according to one surgeon.
Heidelberg Engineering Announces Expansion To New US Corporate Headquarters
Vista, CA – Due to continuing, rapid growth, Heidelberg Engineeringannounced plans to move its corporate US headquarters to the Carlsbad Research Center in Carlsbad, California at the beginning of April. The company will also move its service center to…
Femtosecond-Guided LASIK Enhancement Has Minimal Trauma, Reduced Rate Of Epithelial Ingrowth
A new technique of LASIK enhancement using a femtosecond laser allows for easy flap re-lifting, minimal trauma and significantly reduced rate of epithelial ingrowth, according to one surgeon.
Heidelberg Engineering Announces Expansion To New US Corporate Headquarters
Vista, CA – Due to continuing, rapid growth, Heidelberg Engineeringannounced plans to move its corporate US headquarters to the Carlsbad Research Center in Carlsbad, California at the beginning of April. The company will also move its service center to…
Retinal Surgery System And Lenses From Volk At ARVO
Mentor, Ohio – Volk Optical, the industry leader in aspheric optics, will be exhibiting at the Association for Research in Vision and Ophthalmology (ARVO), May 1 – 4 at the Broward County Convention Center (Fort Lauderdale, Florida), booth 509/511.
Retinal Surgery System And Lenses From Volk At ARVO
Mentor, Ohio – Volk Optical, the industry leader in aspheric optics, will be exhibiting at the Association for Research in Vision and Ophthalmology (ARVO), May 1 – 4 at the Broward County Convention Center (Fort Lauderdale, Florida), booth 509/511.
In A Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard Of Care In Patients With Diabetic Macular Edema At 12 Months
Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study. This study evaluated t…
In A Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard Of Care In Patients With Diabetic Macular Edema At 12 Months
Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study. This study evaluated t…